This article was originally published in Start Up
Cellular Genomics discovers and validates new drug targets, initially those associated with dendritic cells, T cells, and mast cells. It is carrying out classical cell biology studies in parallel with genomic analysis, thereby correlating changing cellular behavior with changes in patterns of gene expression and in protein modification and localization within the cell.
You may also be interested in...
With so much genomics data and putative drug targets to sift through, drug developers cannot risk making research resource allocation decisions before correlating gene and protein function with a disease process. The need has spawned a new generation of post-genomics companies focused on developing tools for validating drug targets, including smart screening methodologies and cell-based assays, and on ways to better organize and characterize genomics and proteomics data.
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.